Spyre Therapeutics Inc (SYRE) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

SYRE ranks #2341 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

SYRE is a top-conviction position for Remedium Capital Partners, LLC — at 28.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in SYRE belongs to FMR LLC, but the position matters far more to Remedium Capital Partners, LLC, who has 28.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its SYRE position for two straight quarters, increasing it by $775.2M to reach $1.2B today.

Capital International Investors has trimmed its SYRE position for two straight quarters, cutting it by $29.6M while still holding $84.8M.

SYRE is down 12.8% today, but institutions show net buying of $2.2B this quarter — a divergence between today's price move and the underlying institutional flow.

SYRE reported a net loss of $178.9M over the trailing twelve months.

• Not yet profitable — net loss of $178.9M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$206.8M to -$178.9M
• Operating cash flow was negative, using $169.3M in cash
• Current ratio of 13.25x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range